Ignacio Muñoz-Sanjuan: “We may see a Huntington’s therapy approved in 2026. It is a day for hope: while the therapy will at first be limited, access will increase in the years ahead”
24/09/2025 Ignacio Muñoz-Sanjuan, neuroscientist and founder of the non-profit Factor-H, has expressed optimism that an experimental gene therapy for Huntington’s disease, developed by uniQure and called AMT-130, could receive regulatory approval in the first half of 2026, in what is a very significant milestone for patients and families affected by the disorder. “It is a […]
English 
Español 
Português do Brasil